Detail

Keywords

Arthritis, Psoriatic; Arthritis, Rheumatoid; Biomarkers, Pharmacological; Clinical Trial; Musculoskeletal Diseases; Observational Study; Patient Outcome Assessment; Quality of Life; Sjogren's Syndrome; Treatment Outcome

Research group(s)

• Outcomes in musculoskeletal and inflammatory diseases
  Members:
  Peter Mandl
  Paul Studenic
• Musculoskeletal Imaging
  Head: Peter Mandl
  Research Area: Optimisation of existing- and development of novel imaging methods to investigate the musculoskeletal system in rheumatic & musculoskeletal diseases.
  Members:
  Peter Mandl
  Paul Studenic

Research interests

1. Outcomes analyses of longitudinal observational clinical, radiographic and laboratory data prospectively assessed in patients with inflammatory arthritis (rheumatoid arthritis) . A focous is set to prediction of response, patient reported outcomes and interactions with objectively assessed outcomes.
2. Analyses of novel biomarkers within collaborative projects to estimate the relevance for further characterizing the disease / disease progression or potentially predicting treatment response.
3. Outcomes Assessment in musculoskeletal diseases and burden of disease in in people with inflammatory joint diseases and exploration of actions to increase quality of life
4. Evolvement for integration of e-health, particularly m-health tools in clinical practice

Techniques, methods & infrastructure

• Developing observational studies for biomarker and clinical outcomes assessment.
• Clinical database development and quality control.
• Epidemiologic and statistical methods, concerning Risk, Reliability, Validity and longitudinal Studies
• RCTs & Systematic Reviews
• Digital endpoint development
• Social Media Impact Analyses

Grants

• Cotidiana (2021)
  Source of Funding: FFG (Austrian Research Promotion Agency), AAL
  Principal Investigator
• Multimodal Assessment Sjögren (0)
  Source of Funding: City of Vienna, Hochschuljubiläumsstiftung
  Coordinator of the collaborative project
• Rheumabuddy 4.0 (0)
  Source of Funding: FFG (Austrian Research Promotion Agency), Eurostars
  Principal Investigator
• STRATA-FIT (0)
  Source of Funding: EU, HORIZON-RIA
  Principal Investigator

Selected publications

1. Studenic, P. et al. (2022) ‘American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision’, Annals of the Rheumatic Diseases, 82(1), pp. 74–80. Available at: http://dx.doi.org/10.1136/ard-2022-223413.
2. Studenic, P. et al. (2021) ‘Torque Teno Virus quantification for monitoring of immunomodulation with biologic compounds in the treatment of rheumatoid arthritis’, Rheumatology, 61(7), pp. 2815–2825. Available at: http://dx.doi.org/10.1093/rheumatology/keab839.
3. Studenic, P. et al. (2022) ‘Prospective Studies on the Risk of Rheumatoid Arthritis: The European Risk RA Registry’, Frontiers in Medicine, 9. Available at: http://dx.doi.org/10.3389/fmed.2022.824501.
4. Studenic, P. et al. (2015) ‘Reliability of patient-reported outcomes in rheumatoid arthritis patients: an observational prospective study’, Rheumatology, 55(1), pp. 41–48. Available at: http://dx.doi.org/10.1093/rheumatology/kev282.
5. Studenic, P. et al. (2012) ‘Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity’, Arthritis & Rheumatism, 64(9), pp. 2814–2823. Available at: http://dx.doi.org/10.1002/art.34543.